Posts by Sandra Ansanay-Alex
planetary Switzerland: Scaling Mycoprotein Production Through Strategic Expansion
Geneva-based biomanufacturing platform planetary is making significant strides in the alternative protein sector through a combination of strategic acquisitions, IP breakthroughs, retail partnerships, and government-backed expansion plans. The company has positioned itself as continental Europe’s only viable industrial mycoprotein producer, leveraging cutting-edge fermentation technology to create sustainable protein alternatives. Strategic Acquisition of Libre Foods…
Read MoreTwo UNIGE researchers receive ERC grants
Prof. Pedro Herrera and Prof. Giuseppe Iacobucci both receive €150,000 in funding from the European Research Council (ERC) The European Research Council (ERC) announced the first group of researchers who will receive ERC Proof of Concept Grants in 2025. Two scientists from UNIGE are among those selected. Pedro Herrera, Professor in the Department of Genetic…
Read MoreNestlé Partners with IBM Research to Use AI in New Packaging Developments
Nestlé R&D is partnering with IBM Research to develop new tools that leverage the power of Artificial Intelligence and deep tech to bring breakthrough innovations to life. This research collaboration has led to the development of a generative AI tool that can identify novel high-barrier packaging materials. Packaging helps to protect food and beverages while also preventing food waste. Nestlé tries to…
Read MoreDay One Innovation Showcase
The Day One Innovation Showcase for healthtech promising startups is taking place on 10 and 11 December 2025 in Basel The Showcase is an elite event, tailor-made for investors, startups and potential industry clients, fostering networking, pitching, business exploration and a deep dive into the healthtech startup ecosystem. During the two-day program you…
Read MoreADM Opens R&D Center Dedicated to Animal Health and Wellness at Biopôle
Located ar Biopôle Lausanne in canton of Vaud, the new innovation hub will focus on advanced microbiome research for farm and companion animals ROLLE, Switzerland—ADM (NYSE: ADM), a global leader in innovative solutions from nature, has opened a new research and development (R&D) center focused on advancing research into animal microbiomes, and developing tailored…
Read MoreFirst Ventures
Apply before 1 September 2025 to First Ventures and get up to CHF 150’000 from Gebert Rüf Stiftung With «First Ventures», Gebert Rüf Stiftung supports bachelor’s and master’s students of Swiss Universities of Applied Sciences UAS who are developing an innovative business idea out of their studies towards the market. The support includes progressing…
Read MoreFribourg Scientists Help Uncover Erythrocytosis Mutation
An international team of researchers, including five scientists from the University of Fribourg, has identified genetic mutations responsible for certain forms of erythrocytosis — a rare condition in which the body overproduces red blood cells. The findings shed new light on an often-misunderstood disease that can lead to dangerous blood clots and other serious health…
Read More48th IHF World Hopital Congress
The 48th IHF World Hopital Congress is taking place from 10 to 13 November 2025 in Geneva IHF supports hospital leaders to deliver low-carbon, resilient healthcare. The event will highlights the actions – and benefits – of sustainable healthcare throughout the scientific programme, as well as in pre-Congress activities and visits. At this unique…
Read MoreStartup Nights
Startup Nights, one of the largest startup event in Switzerland, is taking place on 6-7 November in Winthertur Startup Night Pitching showcases startups tackling global challenges with technologies that deliver tangible social or ecological value! A unique opportunity to gain visibility, build recognition, and showcase your solution to investors, leading innovation experts in Switzerland,…
Read MoreAzureCell Therapies secures CHF 150,000 from Venture Kick
AzureCell Therapies, a Biotech spin-off from the University of Geneva, has received CHF 150,000 from Venture Kick to deliver cell-based treatments that replace damaged neurons in Parkinson’s patients. Parkinson’s disease is an increasingly prevalent neurological disorder that affects over 10 million people worldwide. Current treatments only manage symptoms and fail to halt the disease’s…
Read More